improving nature s own defense mechanisms Company presentation

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "improving nature s own defense mechanisms Company presentation"

Transcription

1 improving nature s own defense mechanisms Company presentation August 2013

2 Lytix Biopharma AS Norwegian non-listed company Founded 2003 Tromsø Aims to develop novel therapeutics for areas of high unmet needs: Infectious diseases Oncology Oslo

3 Lytix Biopharma is a clinical-stage company 3

4 4 Strong IPR State of the art patent strategy 12 patent families 21 patents granted 65 patents pending Broad patent protection covering Technology platform Method of use Composition of matter from Additional features Patent base allows for the development of multiple product candidates Patents applied for major markets

5 5 Highly competent management team Unni Hjelmaas CEO Extensive senior management experience from Roche, former General Manager for Roche Norway Several positions in sales and marketing, substantial experience is in oncology, life cycle management, international strategy and marketing experience from Roche HQ in Basel Former Chairman and current member of the Board of the Norwegian Pharma Industry Association Cand.pharm, Pharmacy from the University of Oslo Gunnar Sælid Senior Advisor Previous CEO of Lytix Biopharma, extensive senior management experience from the pharmaceutical industry (Nycomed, GE Health and Novartis), life science research and business facilitation (The National Hospital, Oslo Research Park) and seed finance (Start Foundation) Previously life science board positions (The Biotechnology Centre of Oslo, The Norwegian Research Council) MSc in biochemistry Øystein Rekdal, PhD Co-founder and director, Oncology Research CEO of Lytix Biopharma from establishment in 2003 Extensive research background in peptide chemistry, biochemistry and tumour biology PhD from the University of Tromsø, Professor in the Medical Biochemistry Department in the Faculty of Medicine at the University of Tromsø Wenche Marie Olsen, DrPhilos COO Broad experience within research, development and management of new drug products in pharmaceutical and biotech industry Former CEO of Lauras, various positions in Nycomed/GE Healthcare PhD in medical biochemistry from the National Hospital, University of Oslo Anders Fugelli, PhD Director, Business Development Strong track record in management roles in several Norwegian companies in the Life Sciences sector Formerly GlaxoSmithKline PhD in pharmacology/biochemistry from the University of London John S. Svendsen, PhD Co-founder and Director, Discovery Research Extensive research experience in medical biochemistry, synthetic organic chemistry and medicinal chemistry, specialising in antibacterial peptides Visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at MIT PhD from the University of Tromsø, Professor of organic chemistry at the University of Tromsø

6 6 Experienced Board of Directors Knut Eidissen Chairman Owner and managing director of the consulting and investment company Picasso Extensive experience as a board member from both private and as public limited companies Strong track record in creating shareholder value, e.g. as chairman of the oil-and oil service company, Altinex Siri Fürst Thorough experience in the pharmaceutical sector, e.g., from Nycomed, where she held the position as director administration, strategy and business development and as Vice President Investor Relations Currently partner in Considium Consulting Group and a board member with SNN Invest Karl-Johan Jakola - Vice Chairman Managing partner of NorInnova Forvaltning Substantial experience from business development and financing of start-up companies Alf Lindberg Professor in clinical bacteriology, has been Chief Scientific Officer and Head of R&D at Wyeth Lederle Vaccines Former Executive VP of R&D at Pasteur Merieux Connaught, member of the Nobel Assembly and member of the Board of Directors of the Nobel Foundation Serves on several Scientific Advisory Boards. Currently he is the CEO of Nobel Web Håvard Selby Ebbestad CEO of Fürst Medisinsk Laboratorium, one of the leading medical laboratories in Europe Former Managing Director of Zeneca, Pharmacia and Pfizer in Norway and Chairman of the board of LMI (The Association of the Pharmaceutical Industry in Norway) Steinar Høeg Director External Affairs Europe in AstraZeneca since 2010 Former Marketing Company President for Astra/AstraZeneca in Norway, Sweden and in the Nordics, member of the European Management Team, member of the Norwegian Trade Association and Chair of the Swedish trade association for research based pharmaceutical companies John Sigurd Svendsen (see management CVc)

7 7 Lytix Biopharma scientific background T=5 minutes LTX-109 (infection) LTX-315 (cancer) Lactoferrin Lactoferricin The lactoferrin protein is found in milk and is known to have direct anti-microbial activity and cancer immune modulatory effects Structure-activity-relationship studies have resulted in the design of two optimal molecules originating from the Company s technology platform; the anti-infective drug LTX-109 and the cancer immune therapeutic drug LTX-315

8 8 Highly efficient peptides Ultra rapid membrane disruption Time: 0 min 5 min 10 min 20 min Host defence peptides form the cornerstone of the body s protection against a broad spectrum of harmful micro-organisms Some host defence peptides kill micro-organisms by direct disruption of the cell membrane (lysis). Such lytic peptides represent a novel class of drugs More recent research has shown that some host defence peptides have powerful anti-cancer effects. These peptides induce release of danger signals and tumor associated antigens (TAAs) from the tumor leading to protective immune responses

9 LTX-315 induces tumor regression and protective immunity 9 Kills cancer cells, including MDR phenotypes Knocks out tolarized tumor-infiltrating lymphocytes (TILs) Signals danger and causes inflammation Releases tumor-associated antigens (TAAs) Attracts new TILs Immune-active tumor micro-environment favors response to check-point blockade inhibitors. LTX-315 may therefore represent an ideal synergistic combination partner in future cancer treatment

10 10 LTX-109 is a well-documented drug candidate Fast acting, bactericidal antimicrobial drug Broad spectrum of activity Low propensity for resistance development Effective against multi-drug resistant bacteria Effective against biofilms

11

improving nature s own defense mechanisms Shareholder meetings

improving nature s own defense mechanisms Shareholder meetings improving nature s own defense mechanisms Shareholder meetings April 2015 Lytix Biopharma AS Norwegian non-listed company Founded 2003 Tromsø Technology platform- de novo designed host defence peptides

More information

An Exclusive Interview with Dr Jan-Anders Karlsson

An Exclusive Interview with Dr Jan-Anders Karlsson Dr Jan-Anders Karlsson took over the helm as the CEO of S*BIO from January 2005. He has extensive experience in the pharmaceutical industry, with many proven successes in the drug discovery area. Dr Karlsson

More information

Welcome and objectives - Luigi Costa, CEO

Welcome and objectives - Luigi Costa, CEO Welcome and objectives - Luigi Costa, CEO Market Capital Day, November 17 th 2015 Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com 0 Forward-looking statements This

More information

Biomedical Accelerator Fund. Office of Technology Development Harvard University

Biomedical Accelerator Fund. Office of Technology Development Harvard University Biomedical Accelerator Fund Office of Technology Development Harvard University Curtis Keith, Chief Scientific Officer May 21, 2012 Mission of Harvard s Office 2 Organizational Structure of Harvard OTD

More information

PCI Biotech Holding ASA - Second Quarter Report 2008

PCI Biotech Holding ASA - Second Quarter Report 2008 PCI Biotech Holding ASA - Second Quarter Report 2008 Highlights Demerger and Initial Public Offering at Oslo Axess in June Raised NOK 60 million Per Walday, PhD hired as new CEO Board has been strengthened

More information

New Tools. Diseases. for Research on. R&D for Neglected Patients. Scientific Symposium. conference programme. In collaboration with.

New Tools. Diseases. for Research on. R&D for Neglected Patients. Scientific Symposium. conference programme. In collaboration with. Wednesday, 4 December 2013 Institut Pasteur, Paris, France R&D for Neglected Patients Scientific Symposium New Tools for Research on Kinetoplastid Diseases conference programme Speakers & chairs Scientific

More information

Grow your business via Västerbotten. Regional Partner

Grow your business via Västerbotten. Regional Partner Grow your business via Västerbotten Anti-infective research in Umeå Unique insight on the pathogenicity of microbes and novel approaches on antibiotics 3 universities with 35.000 students (Umeå University

More information

The Active Biotech Group Half-Year Accounts January June 2000

The Active Biotech Group Half-Year Accounts January June 2000 The Active Biotech Group Half-Year Accounts January June 2000 Results according to schedule, MSEK -59 (-75 previous year) Vaccine sales increase by 20% Continued positive development for Dukoral +42% Aventis

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Anti-infective research in Umeå. Regional Partner

Anti-infective research in Umeå. Regional Partner Anti-infective research in Umeå Unique insight on pathogenicity of microbes and novel approaches on antibiotics 3 universities with 35.000 students (Umeå University www.umu.se, Luleå Technical University

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

Guide to submitting your small molecule or therapeutic antibody target

Guide to submitting your small molecule or therapeutic antibody target Guide to submitting your small molecule or therapeutic antibody target Background on MRC Technology Understanding the application review process What MRC Technology looks for in a therapeutic antibody

More information

Egon Zehnder International

Egon Zehnder International Egon Zehnder I. ID info about yourself Work-setting Preferences Personal Skills Inventory Motivational Factors III. Targeting your employer Narrowing the field Aligning credentials Optimizing documents

More information

THE CENTRE FOR PHARMACEUTICAL ONCOLOGY

THE CENTRE FOR PHARMACEUTICAL ONCOLOGY THE CENTRE FOR PHARMACEUTICAL ONCOLOGY Application for Membership Send Completed Form to: sam.dalfonso@utoronto.ca Name (Last, First): Current Position: o Professor o Associate Professor o Assistant Professor

More information

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

Increasing Innovation in R&D - Seizing early stage external growth opportunities

Increasing Innovation in R&D - Seizing early stage external growth opportunities Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

Baxalta 2015 Investor Conference May 19, 2015

Baxalta 2015 Investor Conference May 19, 2015 Eric W. Foster is expected to serve as Senior Vice President and Chief Information Officer for Baxalta upon completion of the separation. Mr. Foster brings more than 15 years of IT leadership experience

More information

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES HEALTHCARE BIOTECHNOLOGY In Spain the development of ageing medicine presents an excellent business opportunity because the population

More information

Curriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education

Curriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education Curriculum Vitae Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details Private Address: Date, Place of Birth: Marital Status: Nationality: Languages: Stresemannstraße 9, 93477 Maintal, Germany, Tel. +49

More information

Resumen Curricular de los Profesores. Jesse Boehm

Resumen Curricular de los Profesores. Jesse Boehm Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub

More information

Immune cells from healthy people pulverise cancer

Immune cells from healthy people pulverise cancer Published on ScienceNordic (http://sciencenordic.com) Home > Printer-friendly PDF > Printer-friendly PDF Immune cells from healthy people pulverise cancer Health[1] Health[1]Cancer research [2]immune system

More information

Eudendron: an Innovative Biotech Start-up

Eudendron: an Innovative Biotech Start-up Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description

More information

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting - A Microbiology Services Company Lab Services Research - Consulting - Regulatory Company description is a microbiology services company specializing in antiinfective discovery and development for the pharmaceutical,

More information

Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd.

Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd. Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd. Roche recognizes changes in China Strong economic development

More information

Clinical Research Workshop

Clinical Research Workshop Clinical Research Workshop Introduction In these activities, pupils learn about how new medicines are developed from the initial idea, through the science that turns them into treatments, to the clinical

More information

For personal use only

For personal use only The Company Announcements Platform ASX Limited By E-lodgement PTX Shareholder Newsletter 9 November 2015, Melbourne, Australia: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company,

More information

Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs

Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs BIO Ventures for Global Health Sharing Innovation in the Fight Against Neglected Tropical Diseases World Intellectual Property

More information

MSc program Pharmaceutical Design and Engineering. Peter Heegaard, Head of Studies DTU Veterinary

MSc program Pharmaceutical Design and Engineering. Peter Heegaard, Head of Studies DTU Veterinary MSc program Peter Heegaard, Head of Studies DTU Veterinary There is a need for Pharma graduates Pharma industry in its widest sense (see next slide) Research institutions (public and private) Consultants

More information

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis Oncoxx Biotech Saverio Alberti Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis INTRODUCTION Oncoxx Biotech S.r.l. is a Cancer Biotech Company as partnership between Chieti University

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

Pharmaceutical & Chemical Sciences Graduate Program

Pharmaceutical & Chemical Sciences Graduate Program Pharmaceutical & Chemical Sciences Graduate Program Pharmaceutical and Chemical Sciences Graduate Program Program Goals and Design: The mission of the Pharmaceutical and Chemical Sciences Graduate Program

More information

Connecting Brain Science and Industry. Tekna Biotechnology Seminar, April 11th 2013, Forskningsparken, Oslo Leif Rune Skymoen

Connecting Brain Science and Industry. Tekna Biotechnology Seminar, April 11th 2013, Forskningsparken, Oslo Leif Rune Skymoen Connecting Brain Science and Industry Tekna Biotechnology Seminar, April 11th 2013, Forskningsparken, Oslo Leif Rune Skymoen Neuroscience The brain The nerve system Dementia/ Alzheimer s disease Parkinson

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

Background: Pathways for the Master s Degree (Thesis and Non Thesis)

Background: Pathways for the Master s Degree (Thesis and Non Thesis) Differences between the Non Thesis (Project) and Thesis Options for the M.S. in Pharmacy with an emphasis in BioPharma Regulatory Affairs Offered by the University of Georgia College of Pharmacy Background:

More information

Selling an Idea. Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore

Selling an Idea. Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Selling an Idea Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Seminar Format XXXX Know Your Stuff Andy Murray The Beetles Read everything in your field Keep up to date Be dedicated

More information

September 29, About BIO

September 29, About BIO The Comments of the Biotechnology Industry Organization on the Discussion Paper on Compulsory Licenses Published by the Department of Industrial Policy and Promotion within India's Ministry of Commerce

More information

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity

More information

Curriculum Vitae. Education. Brief Chronology of Employment. Academic Positions held. Pier Paolo Di Fiore M.D. Ph.D.

Curriculum Vitae. Education. Brief Chronology of Employment. Academic Positions held. Pier Paolo Di Fiore M.D. Ph.D. Pier Paolo Di Fiore M.D. Ph.D. Curriculum Vitae Education 1981 - M.D., summa cum laude, University of Naples, 2nd Medical School, Naples, Italy 1984 - Board in Oncology, summa cum laude, University of

More information

BioLineRx Ltd. (Translation of registrant s name into English)

BioLineRx Ltd. (Translation of registrant s name into English) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2016

More information

2014 Report: biotechnologies in the Italian pharmaceutical sector

2014 Report: biotechnologies in the Italian pharmaceutical sector 2014 Report: biotechnologies in the Italian pharmaceutical sector In collaboration with Assobiotec Executive summary Executive summary Executive summary Biotechnologies have always influenced all spheres

More information

William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites

William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology or Medicine with one half jointly to William C. Campbell and Satoshi Ōmura for their discoveries

More information

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000

More information

Monoclonal antibody (mab) products are currently a fast

Monoclonal antibody (mab) products are currently a fast Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,

More information

Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121

Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 NHLBI SAN DIEGO INNOVATION CONFERENCE JUNE 11, 2013 Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 Agenda Speaker Bios 10:30-11:00 a.m. Registration 11:00-11:15 a.m. Welcome Remarks

More information

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

Clinical medicine in 1987

Clinical medicine in 1987 Clinical medicine in 1987 Rheumatoid arthritis Crohn s disease Triumph of translational medicine Cytokine-targeting antibodies Leukocyte adhesion blockers Kinase inhibitors (cancer, chronic inflammatory

More information

MSC IN MEDICINAL CHEMISTRY

MSC IN MEDICINAL CHEMISTRY faculty of health and medical sciences university of copenhagen MSC IN MEDICINAL CHEMISTRY det sundhedsvi københavns univer Master s programme at the University of Copenhagen msc in medicinal chemistry

More information

SIPBS Portfolio. 2012-13 Entry

SIPBS Portfolio. 2012-13 Entry SIPBS Portfolio 2012-13 Entry MSc Programmes Existing: MSc Pharmaceutical Analysis MSc Analysis of Medicines (distance learning) MSc Clinical Pharmacy New Programmes just launched for Sept 2012 entry:

More information

Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights

Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights ADVANCED TE CHNOLOGY P ROGRAM The Advanced Technology Program Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights April 2006 National Institute of Standards and Technology

More information

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05 Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

FACULTY OF MEDICAL SCIENCE

FACULTY OF MEDICAL SCIENCE Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research

More information

DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com DiaGenic ASA www.diagenic.com Slide #1 DiaGenic.

DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com DiaGenic ASA www.diagenic.com Slide #1 DiaGenic. DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com www.diagenic.com DiaGenic ASA Slide #1 UK Press Coverage Slide #2 Markets: Large, fast growing. Unmet medical

More information

Medical & Health Sciences

Medical & Health Sciences School of Postgraduate Studies Medical & Health Sciences (MSc /PhD by Research) 2016 What Is IMU s Medical & Health Sciences (by Research) Programme About? Overview Postgraduate research forms a major

More information

Global Antibacterial Drugs Market

Global Antibacterial Drugs Market Brochure More information from http://www.researchandmarkets.com/reports/3498706/ Global Antibacterial Drugs Market 2015-2019 Description: About antibacterial drugs Antibacterial drugs are chemical compounds

More information

Postgraduate education in clinical pharmacy from specialisation led by professional organisations to an academic degree within the Bologna framework

Postgraduate education in clinical pharmacy from specialisation led by professional organisations to an academic degree within the Bologna framework Postgraduate education in clinical pharmacy from specialisation led by professional organisations to an academic degree within the Bologna framework Professor Espen Molden School of Pharmacy, University

More information

company overview A P R I L

company overview A P R I L company overview APRIL 2016 our focus INNOVATION in Aesthetics and Dermatology DISCOVERY CLINICAL DEVELOPMENT COMMERCIALIZATION 2 / CONFIDENTIAL and PROPRIETARY the sienna opportunity CLEAR STRATEGY for

More information

Immunology and Microbiology

Immunology and Microbiology name of programme short description coordinator(s) participating labs/pis Immunology and Microbiology The study of infectious diseases and the immune system is vital to our society as we continue to fight

More information

Ole Petter Ottersen. M.D. University of Oslo Ph.D. University of Oslo Rector (President) of the University of Oslo 2009-

Ole Petter Ottersen. M.D. University of Oslo Ph.D. University of Oslo Rector (President) of the University of Oslo 2009- Curriculum Vitae Ole Petter Ottersen Contact E-mail: o.p.ottersen@medisin.uio.no Tel: +47-22 85 63 03 Cell: +47 90 13 26 10 Postal address: P.O. Box 1072 Blindern N-0316 Oslo Norway Visiting address: University

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

Biotec s Soluble Beta-Glucan (SBG ) in clinical applications and its scientific platform

Biotec s Soluble Beta-Glucan (SBG ) in clinical applications and its scientific platform Biotec s Soluble Beta-Glucan (SBG ) in clinical applications and its scientific platform Arctic Biotech Seminar 30 th November 2015 CS Rolf E Engstad Agenda Company Soluble beta-glucan (SBG ) as PAMP SBG

More information

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,

More information

Active Biotech Group Interim Report 1 January 30 September 1999

Active Biotech Group Interim Report 1 January 30 September 1999 Active Biotech Group Interim Report 1 January 30 September 1999 The new annual forecast shows a considerably better result. Sale of the property in Solna expected to be completed before the end of the

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

Contents. Page 1 of 21

Contents. Page 1 of 21 Programme-specific Section of the Curriculum for the MSc Programme in Biochemistry at the Faculty of Science, University of Copenhagen 2009 (Rev. 2015) Contents... 1 1 Title, affiliation and language...

More information

New Solutions for Sea Lice Control. Ian Thompson Head Global Technical Services, Aqua Pharmaceuticals

New Solutions for Sea Lice Control. Ian Thompson Head Global Technical Services, Aqua Pharmaceuticals New Solutions for Sea Lice Control Ian Thompson Head Global Technical Services, Aqua Pharmaceuticals Novartis is a world-leading healthcare company Leading market position One of 20 largest companies by

More information

IMI2: why, what, how?

IMI2: why, what, how? IMI2: why, what, how? The Right prevention and treatment, to the right patient, at the right time Isabelle Thizon-de Gaulle VP, Strategic initiatives & Scientific relations Sanofi R&D Innovative Medicines

More information

A targeted approach to infectious diseases and microbiology

A targeted approach to infectious diseases and microbiology What is a Technological Research Institute? A Technological Research Institute is an interdisciplinary institute bringing together industry and public research skills through medium-to long-term strategic

More information

www.iproteos.com Corporate Presentation November, 2013

www.iproteos.com Corporate Presentation November, 2013 www.iproteos.com Corporate Presentation November, 2013 The company Iproteos is an early-stage drug development company founded in 2011: Spin-Out from Institute for Research in Biomedicine (IRB Barcelona)

More information

We use Reaxys intensively for hit identification, hit-to-lead and lead optimization.

We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical

More information

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015 Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,

More information

Name Date Class. This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread.

Name Date Class. This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread. Fighting Disease Name Date Class Infectious Disease This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread. Use Target Reading Skills Before you read,

More information

REINVENTING THE SCIENCE OF DRUG DISCOVERY

REINVENTING THE SCIENCE OF DRUG DISCOVERY REINVENTING THE SCIENCE OF DRUG DISCOVERY The science of pharmacology and the business of drug discovery are ready for reinvention. Using big data and advanced analytics to combat disease Over the past

More information

company overview M A R C H

company overview M A R C H company overview MARCH 2016 our focus INNOVATION in Aesthetics and Dermatology DISCOVERY CLINICAL DEVELOPMENT COMMERCIALIZATION 2 / CONFIDENTIAL and PROPRIETARY the sienna opportunity CLEAR STRATEGY for

More information

Double degrees with University of Sussex, UK

Double degrees with University of Sussex, UK BIOMEDICAL SCIENCE Double degrees with University of Sussex, UK Faculty of Science (International Program), Mahidol University (SIM) has developed Dual Degree Programs in cooperation with University of

More information

SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS

SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS Graduate Programs CELL, MOLECULAR, AND DEVELOPMENTAL BIOLOGY CLINICAL

More information

Jobbetegnelser for det nuværende job i branchen

Jobbetegnelser for det nuværende job i branchen Jobbetegnelser for det nuværende job i branchen Administrerende direktør (CEO) Academic, Project manage Advanced Business Analyst Advanced Business Analyst, IT&CD, IT System Management Analytical Service

More information

What You Need to Know About Lung Cancer Immunotherapy

What You Need to Know About Lung Cancer Immunotherapy What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer

More information

2015 / 2016 Awards Criteria and Submission Information

2015 / 2016 Awards Criteria and Submission Information 9 th Annual ViE Awards 2015 / 2016 Awards Criteria and Submission Information In association with: Dear colleague, The Vaccine Industry Excellence (ViE) Awards have been created to honor and generate recognition

More information

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in

More information

APOGEE REPORTS FISCAL 2007 RESULTS

APOGEE REPORTS FISCAL 2007 RESULTS F O R I M M E D I A T E R E L E A S E Apogee Investor Contact: Paul J. Murphy Chief Financial Officer and Vice President of Finance Telephone: (781) 551-9450 APOGEE REPORTS FISCAL 2007 RESULTS NORWOOD,

More information

BIOSKETCH. Degrees: Cand. real. 1971, Dr. philos. 1978. University of Bergen, Norway

BIOSKETCH. Degrees: Cand. real. 1971, Dr. philos. 1978. University of Bergen, Norway BIOSKETCH Johan R. Lillehaug Born: 25.09.45 Home address: Ibsensgate 89, 5052 Bergen Nationality: Norwegian Present position: Department Chairman (2004- ) and Professor in biotechnology (1987-), Department

More information

August 28, 2012. Company Update Commerzbank Sector Conference Week

August 28, 2012. Company Update Commerzbank Sector Conference Week August 28, 2012 Company Update Commerzbank Sector Conference Week Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Biomanufacturing keeps moving along on SouthCoast

Biomanufacturing keeps moving along on SouthCoast Biomanufacturing keeps moving along on SouthCoast By LAURA PEDULLI Contributing writer September 21, 2014 12:00 AM Dr. Wendell Yang of Imgen BioSciences, left, and Dr. Meijia Yang of Boston 3T Biotechnologies

More information

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines The R&D Process: Long, Complex, and Costly Average cost of R&D is $1.2 Billion The Current Challenge

More information

Actionable Insights into Health Policy, Practice and Outcomes Through Research and Big Data - with a Spotlight on Oncology

Actionable Insights into Health Policy, Practice and Outcomes Through Research and Big Data - with a Spotlight on Oncology Actionable Insights into Health Policy, Practice and Outcomes Through Research and Big Data - with a Spotlight on Oncology Attend the Virtual Meeting in HE-Xpo Wednesday, Feb. 18, 2015 Session One: 9:30

More information

Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine

Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Martin LeBlanc, President and CEO, Caprion The 2014 ISPIM Americas Innovation Forum October 6, 2014 1 CHALLENGES FOR

More information

New Millennium Indian Technology Leadership Initiative

New Millennium Indian Technology Leadership Initiative New Millennium Indian Technology Leadership Initiative A Unique Indian Public-Private Partnership Dr. D. Yogeswara Rao Head Technology Networking and Business Development Division Council of Scientific

More information

Immunity Unit Test Z

Immunity Unit Test Z Immunity Unit Test Z Name MB Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Which of the pathogens in Figure 31.1 cause disease by taking over healthy

More information

Translational Development of IMX101 A Best Practice Model 8. International VPM Days Hannover, September 17th, 2015 Dr.

Translational Development of IMX101 A Best Practice Model 8. International VPM Days Hannover, September 17th, 2015 Dr. Translational Development of IMX101 A Best Practice Model 8. International VPM Days Hannover, September 17th, 2015 Dr. Alexander Werner Company History Technische Universität München (Prof. Dr. Markus

More information

Main Conference Agenda

Main Conference Agenda Sponsored by: (Co-located with Bioequivalence: Intersection between Science & Regulatory Conference) Main Conference Agenda Day One Wednesday, November 5 th, 2014 7:30 Registration Opens & Continental

More information

Quality assurance of doctoral education in an interfacultary Graduate School

Quality assurance of doctoral education in an interfacultary Graduate School Quality assurance of doctoral education in an interfacultary Graduate School Utrecht University Graduate school of Life Sciences Utrecht, The Netherlands Saskia Ebeling PhD Administrative Secretary to

More information

Sarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota 55403 612.202.6805 shaecker@celltherapygroup.com

Sarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota 55403 612.202.6805 shaecker@celltherapygroup.com Sarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota 55403 612.202.6805 shaecker@celltherapygroup.com PROFILE Successful Senior Executive, skilled in Corporate Development including Business

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

Frequently Asked Questions

Frequently Asked Questions Frequently Asked Questions 1. What is Human Longevity Inc.? Human Longevity Inc. (HLI) is a genomics-based, technology-driven company creating the most comprehensive database of whole genome, phenotype

More information

BioMmune Technologies Inc. Corporate Presentation 2015

BioMmune Technologies Inc. Corporate Presentation 2015 BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical

More information

A vaccine for rheumatoid arthritis

A vaccine for rheumatoid arthritis A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright

More information